Working… Menu
Trial record 6 of 22 for:    "Chronic Inflammatory Demyelinating Polyneuropathy" | "Immunoglobulins, Intravenous"

Panzyga in CIDP Administered at Different Infusion Rates (Panzyga-CIDP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03166527
Recruitment Status : Unknown
Verified May 2017 by Vera Bril, University Health Network, Toronto.
Recruitment status was:  Not yet recruiting
First Posted : May 25, 2017
Last Update Posted : May 25, 2017
Information provided by (Responsible Party):
Vera Bril, University Health Network, Toronto

Brief Summary:
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a treatable form of peripheral neuropathy with suspected autoimmune cause. The current first-line treatment is IVIG (immune globulin), which is infused in a set regimen that requires 4-5 hours in a hospital day unit, taking up resources such as nursing time and hospital space. Chronic treatment is required in most cases.

Condition or disease Intervention/treatment Phase
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drug: Immune Globulin 10% Intravenous Solution Phase 3

Detailed Description:

The proposed trial will be an exploratory, open-label, single-centre, phase IIIb safety, tolerability and efficacy study, wherein each patient acts as their own control. The primary outcome measure is safety and tolerability of panzyga in patients with active CIDP at standard and high infusion rates as measured by:

  • Occurrence of all adverse events with focus on adverse drug reactions (ADRs)
  • The secondary outcomes include: Patients' treatment satisfaction, proportion of patients successfully achieving higher infusion rates, health utilities associated with treatment, proportion of responders to treatment based on change in clinical scores, grip strength, and quality of life measures. The total sample size is 25-30 patients, based on a difference of 30% in adverse events rates between the standard infusion rate and the maximum rate tolerated by each patient.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Each patient with active CIDP will receive Panzyga (immune globulin) at standard and high infusion rates and will act as their own control.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Open-Label, Phase IIIb Study Evaluating the Safety, Tolerability and Efficacy of Panzyga® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Administered at Standard and High Infusion Rates
Estimated Study Start Date : June 1, 2017
Estimated Primary Completion Date : December 15, 2018
Estimated Study Completion Date : December 15, 2018

Arm Intervention/treatment
Open Label study
open label study using Panzyga immune globulin 10% intravenous solution with no placebo.
Drug: Immune Globulin 10% Intravenous Solution
standard Immune lobulin 10% intravenous solution infusion at standard and high infusion rates.
Other Name: Panzyga IVIG

Primary Outcome Measures :
  1. Occurrence of all adverse events with focus on adverse drug reactions (ADRs) [ Time Frame: 2 years ]
    adverse drug reactions

Secondary Outcome Measures :
  1. treatment satisfaction [ Time Frame: 2 years ]
    completion of questionnaire

  2. proportion of patients successfully achieving higher infusion rates [ Time Frame: 2 years ]
    descriptive analysis of number of patients

  3. health utilities [ Time Frame: 2 years ]
    completion of questionnaire

  4. proportion of responders to treatment based on change in clinical scores [ Time Frame: 2 years ]
    completion of scale

  5. grip strength [ Time Frame: 2 years ]
    measurements in kPa

  6. quality of life measures [ Time Frame: 2 years ]
    completion of scale

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with diagnosis of definite or probable CIDP according to the EFNS/PNS Guideline 2010; including patients with Multifocal Acquired Demyelinating Sensory And Motor Neuropathy (MADSAM) or pure motor CIDP
  2. Patients with active disease, i.e. not being in remission.
  3. IVIG naïve patients with clinical indication for IVIG based on progressive or relapsing disease and adjusted INCAT (ONLS) disability score between 2 and 9 (with a score of 2 coming exclusively from leg disability).
  4. Patients already receiving IVIG must be on 3- or 4-weekly IVIG treatment schedule with a calculated monthly dosage between 0.8 g/kg and 2.0 g/kg BW
  5. ≥ 18 years of age
  6. Voluntarily given, fully informed written consent obtained from patient before any study-related procedures are conducted
  7. For enrolment into the Second Phase: At each of the last three infusions in the First Phase, administration of panzyga® had to be at the maximum infusion rate of 0.08 mL/kg/min and good tolerated- assessment by Investigator according to local site practice

Exclusion Criteria:

  1. MMN with conduction block
  2. Patients who previously failed immunoglobulin therapy
  3. Treatment with immunomodulatory/suppressive agents (cyclosporin, methotrexate, mitoxantrone, mycophenolate mofetil or azathioprine) during the six months prior to baseline visit
  4. Patients on or treated with rituximab, alemtuzumab, cyclophosphamide, or other intensive chemotherapeutic regimens, previous lymphoid irradiation or stem cell transplantation during the 12 months prior to baseline visit
  5. Respiratory impairment requiring mechanical ventilation
  6. Myelopathy or evidence of central nervous system demyelination or significant persisting neurological deficits from stroke, or central nervous system (CNS) trauma
  7. Clinical evidence of peripheral neuropathy from another cause such as

    1. connective tissue disease or systemic lupus erythematosus (SLE)
    2. HIV infection, hepatitis, Lyme disease
    3. cancer (with the exception of basal cell skin cancer)
    4. IgM paraproteinemia with anti-myelin associated glycoprotein antibodies
  8. Diabetic neuropathy
  9. Cardiac insufficiency (New York Heart Association [NYHA] III/IV), cardiomyopathy, significant cardiac dysrhythmia requiring treatment, unstable or advanced ischemic heart disease
  10. Severe liver disease (ALAT 3x > normal value)
  11. Severe kidney disease (creatinine 1.5x > normal value)
  12. Hepatitis B, hepatitis C or HIV infection
  13. Thromboembolic events: patients with a history of deep vein thrombosis (DVT) within the last year prior to baseline visit or pulmonary embolism ever; patients with susceptibility to embolism or DVT
  14. Body mass index (BMI) ≥40 kg/m2
  15. Selective IgA deficiency with known anti-IgA antibodies
  16. History of hypersensitivity, anaphylaxis or severe systemic response to immuno-globulin, blood or plasma derived products, or any component of panzyga®
  17. Known blood hyperviscosity, or other hypercoagulable states
  18. Use of other blood or plasma-derived products within three months prior to enrolment
  19. Patients with a past or present history of drug abuse or alcohol abuse within the preceding five years prior to baseline visit
  20. Patients unable or unwilling to understand or comply with the study protocol
  21. Participation in another interventional clinical study with IMP treatment currently or during the three months prior to enrolment
  22. Women who are breast feeding, pregnant, or planning to become pregnant, or are unwilling to use an effective birth control method (such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomized partner) while on study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03166527

Layout table for location information
Canada, Ontario
Toronto, Ontario, Canada, M5G 2C4
Sponsors and Collaborators
Vera Bril

Layout table for additonal information
Responsible Party: Vera Bril, MD, University Health Network, Toronto Identifier: NCT03166527     History of Changes
Other Study ID Numbers: 1001
First Posted: May 25, 2017    Key Record Dates
Last Update Posted: May 25, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Immunologic Factors
Physiological Effects of Drugs